FDA path forward for Probuphine requires study; Titan tumbles
This article was originally published in Scrip
Executive Summary
Shares of Titan Pharmaceuticals plummeted 27.4% on 23 December after the company disclosed the FDA has maintained the need for more clinical data before it will approve the firm's subdermal implant Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate) as a maintenance treatment of opioid dependence.